Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 4/2014

01-04-2014 | Original Article

Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom

Authors: I. E. M. Bultink, N. C. Harvey, A. Lalmohamed, C. Cooper, W. F. Lems, T. P. van Staa, F. de Vries

Published in: Osteoporosis International | Issue 4/2014

Login to get access

Abstract

Summary

The incidence of clinical fractures and the associated factors were assessed in patients with systemic lupus erythematosus (SLE) versus matched controls. We found an increased fracture risk in SLE patients compared to controls. Glucocorticoid use, longer disease duration, neuropsychiatric disease complications and previous osteoporotic fractures were identified as associated factors.

Introduction

The aims of this study were to estimate the risk of clinical fractures in patients with SLE versus matched controls and to evaluate the risk factors associated with clinical fractures in SLE.

Methods

This is a population-based cohort study using the Clinical Practice Research Datalink (from 1987–2012). Each SLE patient (n = 4,343) was matched with up to six controls (n = 21,780) by age and sex. Clinical fracture type was stratified according to the WHO definitions into osteoporotic and non-osteoporotic fracture. Cox proportional hazards calculated relative rates (RR) of clinical fracture and time interaction terms to evaluate the timing patterns of fracture. Clinical fracture rates in SLE patients, stratified by age, gender, type of fracture, disease duration and therapy variables, were compared with those rates in controls.

Results

Follow-up durations were 6.4 years in SLE patients and 6.6 years in controls. SLE patients had a 1.2-fold increased clinical fracture risk compared to controls (adjusted RR = 1.22, 95% CI = 1.05–1.42), and the risk further increased with a longer disease duration. Glucocorticoid (GC) use in the previous 6 months raised the risk of clinical fracture (adjusted RR = 1.27, 95% CI = 1.02–1.58). Cerebrovascular events, seizures and previous osteoporotic fractures were identified as predictors of clinical fractures.

Conclusions

We found an increased risk of clinical fracture in SLE patients compared to controls. GC use in the previous 6 months and longer disease duration are associated with the increased fracture risk in SLE. Patients with neuropsychiatric organ damage or previous osteoporotic fractures are also at increased risk of the occurrence of clinical fractures.
Appendix
Available only for authorised users
Literature
1.
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557PubMedCrossRef
2.
Kalla AA, Fataar AB, Jessop SJ, Bewerunge L (1993) Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 36:1726–1734PubMedCrossRef
3.
Mok CC, Mak A, Ma KM (2005) Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14:106–112PubMedCrossRef
4.
Boyanov M, Robeva R, Popivanov P (2003) Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol 22:318–323PubMedCrossRef
5.
Uaratanawong S, Deesomchoke U, Lertmaharit S, Uaratanawong S (2003) Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 30:2365–2368PubMed
6.
Bultink IE (2012) Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 64:2–8CrossRef
7.
Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52:2044–2050PubMedCrossRef
8.
Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, Wong KC, Chan M, Lam CW, Chu FS, Wong KK, Leung PC, Kwok AY (2009) High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol 36:1646–1652PubMedCrossRef
9.
Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-Castro M (2005) High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus 14:529–533PubMedCrossRef
10.
Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, Muñoz-Guarneros M, Escárcega RO, Jiménez-Hernández M, Munguía-Realpozo P, Sandoval-Cruz M, Delezé-Hinojosa M, López-Colombo A, Cervera R (2009) Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol 28:579–585PubMedCrossRef
11.
Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, Manzi S (1999) Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 42:882–990PubMedCrossRef
12.
Fangtham M, Petri M (2009) Predictors of osteoporotic fracture in SLE [abstract]. Arthritis Rheum 60 Suppl:S110
13.
Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, Gordon C (2005) Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64:111–113PubMedCentralPubMedCrossRef
14.
Lee C, Almagor O, Dunlop DD, Manzi S, Spies S, Ramsey-Goldman R (2007) Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol 34:2018–2023PubMed
15.
Ekblom-Kulberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Julkunen H (2013) Frequency of and risk factors for symptomatic bone fractures in patients with systemic lupus erythematosus. Scand J Rheumatol 42:390–393
16.
Wang SH, Chang YS, Liu CJ, Lai CC, Chen WS, Chen TJ, Wang SJ (2013) Systemic lupus erythematosus is associated with a higher risk of cervical but not trochanteric hip fracture: a nationwide population-based study. Arthritis Care Res (Hoboken) 24:1817–1826
17.
Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808PubMedCrossRef
18.
Rhew EY, Lee C, Eksarko P, Dyer AR, Tily H, Spies S, Pope RM, Ramsey-Goldman R (2008) Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus. J Rheumatol 35:230–236PubMed
19.
Weiss RJ, Wick MC, Ackermann PW, Montgomery SM (2010) Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases: a case–control study with 53,108 patients with fractures. J Rheumatol 37:2247–2250PubMedCrossRef
20.
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4–14PubMedCentralPubMedCrossRef
21.
Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60:e128–e136PubMedCentralPubMedCrossRef
22.
van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG (2000) The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9:359–366PubMedCrossRef
23.
Lalmohamed A, Welsing PM, Lems WF, Jacobs JW, Kanis JA, Johansson H, de Boer A, de Vries F (2012) Calibration of FRAXⓇ 3.1 to the Dutch population with data on the epidemiology of hip fractures. Osteoporos Int 23:861–869PubMedCentralPubMedCrossRef
24.
Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T, de Vries F (2009) Risk of hip/femur fracture after stroke: a population-based case–control study. Stroke 40:3281–3285PubMedCrossRef
25.
de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP (2007) Use of beta-2 agonists and risk of hip/femur fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf 16:612–619PubMedCrossRef
26.
de Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214PubMedCrossRef
27.
Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 20:1499–1506PubMedCentralPubMedCrossRef
28.
Pouwels S, Bazelier MT, de Boer A, Weber WE, Neef C, Cooper C, de Vries F (2013) Risk of fracture in patients with Parkinson’s disease. Osteoporos Int 24:2283–2290PubMedCrossRef
29.
Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D’Cruz D, Griffiths B, Khamashta M, Maddison P, McHugh N, Snaith M, Teh LS, Yee CS, Zoma A, Gordon C (2005) BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 44:902–906PubMedCrossRef
30.
Anonymous (2012) ATC Classification Index with DDDs 2002. Nydalen: WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health
31.
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedCrossRef
32.
Lalmohamed A, Vestergaard P, Klop C, Grove EL, de Boer A, Leufkens HG, van Staa TP, de Vries F (2012) Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med 19:1229–1235CrossRef
33.
Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef
34.
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta M (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28PubMedCrossRef
35.
Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N (2001) Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 28:102–108PubMed
36.
Mok CC, Ying SK, To CH, Ma KM (2008) Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Bone 43:327–331PubMedCrossRef
37.
Jacobs J, Korswagen LA, Schilder AM, van Tuyl LH, Dijkmans BA, Lems WF, Voskuyl AE, Bultink IEM (2013) Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int 24:1827–1833PubMedCrossRef
38.
Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884PubMedCrossRef
39.
Somers EC, Thomas SL, Schoonen WM, Hall AJ (2007) Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum 57:612–618PubMedCrossRef
Metadata
Title
Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom
Authors
I. E. M. Bultink
N. C. Harvey
A. Lalmohamed
C. Cooper
W. F. Lems
T. P. van Staa
F. de Vries
Publication date
01-04-2014
Publisher
Springer London
Published in
Osteoporosis International / Issue 4/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2587-z

Other articles of this Issue 4/2014

Osteoporosis International 4/2014 Go to the issue

Review

Effectiveness and characteristics of multifaceted osteoporosis group education—a systematic review

Original Article

Socioeconomic status in relation to incident fracture risk in the Study of Women’s Health Across the Nation

Letter

Maternal vitamin D status in pregnancy and offspring brain development: authors’ reply to C. Annweiler and O. Beauchet

Case Report

Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment

Original Article

An increase in the incidence of hip fractures in Tangshan, China

Original Article

Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study